Nonhormonal therapy for endometriosis: a randomized, placebo-controlled, pilot study of cabergoline versus norethindrone acetate
| Autor: | Jenny Sadler Gallagher, Catherine Stamoulis, Raymond M. Anchan, Amy D. DiVasta, Mark D. Hornstein, Marc R. Laufer |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
endometriosis
Embryology medicine.medical_specialty nonhormonal therapy Endometriosis Placebo law.invention Randomized controlled trial law Cabergoline Internal medicine medicine norethindrone acetate Adverse effect business.industry Pelvic pain Chronic pain Obstetrics and Gynecology medicine.disease Clinical trial Reproductive Medicine cabergoline Original Article Angiogenesis medicine.symptom business medicine.drug |
| Zdroj: | F&S Reports |
| ISSN: | 2666-3341 |
| DOI: | 10.1016/j.xfre.2021.07.003 |
| Popis: | Objective To estimate the efficacy and safety of a novel nonhormonal therapeutic agent, cabergoline, compared with that of the standard clinical therapy, norethindrone acetate (NETA), for the treatment of endometriosis-associated pain in young women with endometriosis. Design Randomized, double-blind, placebo-controlled pilot study. Setting Tertiary care center. Patient(s) Women (n = 9) with surgically confirmed endometriosis. Intervention(s) A random, double-blind assignment to either NETA (5 mg/day) + placebo twice weekly or cabergoline (0.5 mg) twice weekly + placebo daily for 6 months. Main Outcome Measure(s) We collected the measures of pelvic pain and laboratory parameters every 3 months. Result(s) We observed a decrease in pain scores and increase in pain relief in women randomized to receive cabergoline, who appeared to show similar or more improvements than women treated with NETA. The serum measures of vascular endothelial growth factor receptor 1 declined over 6 months in those who received cabergoline. Cabergoline was well tolerated, and no serious adverse events occurred. Conclusion(s) Safe, effective adjunct treatments are lacking for patients with endometriosis who do not respond to standard care. Because the growth of endometriosis requires angiogenesis, blood vessel growth is an attractive therapeutic target. This pilot study suggests that cabergoline, a vascular endothelial growth factor pathway inhibitor, is an effective therapeutic option for women with chronic pain due to endometriosis. Building upon this investigation, we will conduct larger, randomized trials of cabergoline, advancing research on the best treatments for endometriosis—particularly disease resistant to hormonal therapies. Clinical Trial Registration Number clinicaltrials.gov; registration number NCT02542410. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|